MedTrace Logo

Single-ascending Dose Study of HEC-151 Injection

NCT07376200 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2026-04-29

No results posted yet for this study

Summary

Evaluate the safety, tolerability, PK/PD and immunogenicity characteristics of a single subcutaneous HEC-151 Injection solution in healthy participants

Conditions

  • Healthy Adult Male

Interventions

DRUG

HEC-151 Injection

Subcutaneous injection in the abdominal area

DRUG

Degludec insulin

Subcutaneous injection in the abdominal area

DRUG

Placebo

Subcutaneous injection in the abdominal area

Sponsors & Collaborators

  • Sunshine Lake Pharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-24
Primary Completion
2026-09-05
Completion
2026-09-27

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07376200 on ClinicalTrials.gov